125 results
Page 4 of 7
8-K
EX-99.1
via4r
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
barf2zp 1onaql
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
8-K/A
2tbbjb5cr7ojbsf6 8do
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K/A
EX-10.1
9bhrryod
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
b4j esebogsq
4 Mar 19
Entry into a Material Definitive Agreement
7:05am
424B5
ap24sx5
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
ixnhu
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
pn03bn1 6q7szgtxw
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
30guvj
7 Jan 19
Other Events
7:01am
8-K
EX-10.1
hchzd xw91zfl41d
4 Jan 19
Entry into a Material Definitive Agreement
4:23pm
8-K
EX-99.1
72e2h5zei6virk9deelw
10 Dec 18
Other Events
2:07pm
8-K
EX-99.2
ynv1unsvz7cibq6yd0qo
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
sfl9ejm6 9cbk
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
05zr28k jwmu9syjqzqr
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am
8-K
EX-99.2
rml4g5yqqvaklyt
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am